Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?

Cancer Treatment Reviews

Volumn 40, Issue 10, 2014, Pages 1192-1198

  Arnedos, Monica ^a,b   Soria, Jean Charles ^a,b   Andre, Fabrice ^a,b   Tursz, Thomas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

Author keywords

Metastatic cancer; Personalised medicine; Targeted therapies

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN RECEPTOR; VEMURAFENIB; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARDIOTOXICITY; EYE TOXICITY; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; MEDICAL PRACTICE; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE C KIT; PERSONALIZED MEDICINE; PNEUMONIA; PROTEIN TARGETING; RETINA DETACHMENT; RETINA VEIN OCCLUSION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN TOXICITY; TISSUE STRUCTURE; COMPUTER PROGRAM; ECONOMICS; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; NEOPLASMS; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; GENOMIC INSTABILITY; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SOFTWARE;

EID: 84922989609     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.07.002     Document Type: Review

References (63)

1. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
2. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
3. Hurvitz S.A., Hu Y., O'Brien N., Finn R.S. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013, 39:219-229.
4. Badache A., Hynes N.E. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004, 5:299-301.
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
6. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
7. Bartsch R., Wenzel C., Altorjai G., Pluschnig U., Rudas M., Mader R.M., et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007, 25:3853-3858.
8. Chan A., Martin M., Untch M., Gil M.G., Guillem-Porta V., Wojtukiewicz M., et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006, 95:788-793.
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
10. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
11. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
12. Robidoux A., Tang G., Rastogi P., Geyer C.E., Azar C.A., Atkins J.N., et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 14:1183-1192.
13. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
14. Gelmon K.A., Boyle F., Kaufman B., Huntsman D., Manikhas A., Di Leo A., et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012, 30:LBA671.
15. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014.
16. Cortes J., Fumoleau P., Bianchi G.V., Petrella T.M., Gelmon K., Pivot X., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:1594-1600.
17. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012, 30:2585-2592.
18. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
19. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
20. Travis W.D., Brambilla E., Riely G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
21. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
22. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
23. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
24. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
25. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
26. Gorden A., Osman I., Gai W., He D., Huang W., Davidson A., et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003, 63:3955-3957.
27. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
28. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
29. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer cell 2012, 21:227-239.
30. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
31. Mittendorf E.A., Wu Y., Scaltriti M., Meric-Bernstam F., Hunt K.K., Dawood S., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388.
32. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
33. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
34. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
35. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
36. Soria J.C., Sequist L.V., Gadgeel S., Goldman J., Wakelee H., Varga A., et al. First-in-human evaluation of CO-1686, an irreversible, highly, selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Thorac Oncol 2013, 8. abstract O03.
37. Ranson M., Pao W., Kim D.-W., Kim S.-W., Ohe Y., Felip E., et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J Thorac Oncol 2013, 8:MO21.
38. Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013, 45:1446-1451.
39. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013, 4:1116-1130.
40. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
41. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005, 102:16368-16373.
42. Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012, 18:3462-3469.
43. Board R.E., Ellison G., Orr M.C., Kemsley K.R., McWalter G., Blockley L.Y., et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009, 101:1724-1730.
44. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
45. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
46. Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002, 4:699-704.
47. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
48. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
49. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
50. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
51. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
52. Champiat S., Ileana E., Giaccone G., Besse B., Mountzios G., Eggermont A., et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 2014, 9:144-153.
53. Dupont Jensen J., Laenkholm A.V., Knoop A., Ewertz M., Bandaru R., Liu W., et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011, 17:667-677.
54. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
55. Pastorino U., Bellomi M., Landoni C., De Fiori E., Arnaldi P., Picchio M., et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003, 362:593-597.
56. Tabernero J., Rojo F., Calvo E., Burris H., Judson I., Hazell K., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610.
57. Andre F., Bachelot T., Commo F., Campone M., Arnedos M., Dieras V., et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014, 15:267-274.
58. Nowak F., Soria J.C., Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012, 9:479-486.
59. Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S.R., He J., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013, 31:1023-1031.
60. Boussemart L., Routier E., Mateus C., Opletalova K., Sebille G., Kamsu-Kom N., et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013, 24:1691-1697.
61. Romond E.H., Jeong J.H., Rastogi P., Swain S.M., Geyer C.E., Ewer M.S., et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:3792-3799.
62. van der Noll R., Leijen S., Neuteboom G.H., Beijnen J.H., Schellens J.H. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013, 39:664-672.
63. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.